Tagged with GEN

Europe Based on current discussions by the European Commission, launch conditionalities would not account for the distinct nature of small and mid-sized companies, OMPs and ATMPs. EUCOPE’s Alexander Natz breaks down this aspect of the revision of the general pharmaceutical legislation and why it would prove unsustainable for smaller companies and…

Alvion John Bouros of Greek generics start-up Alvion outlines the company’s rapid development since its foundation back in 2014, its product and market selection strategy within Europe, partnerships, business development, and his ambitious goals for the firm’s future.   [We have] confidence that we will soon become one of the leading…

Americas In 2019 the pharma industry financed some 700 clinical studies in Latin America with investments of more than USD one billion and according to FIFARMA, the leading association of innovators in the region, LatAm currently supports about 10 percent of the world’s clinical research. Local industry leaders discuss the advantages…

Taiwan The latest pharma news from Taiwan, including Gongwin-KY’s lung cancer drug approval in China, Anxo Pharmaceutical/Genovior Biotech alliance, Taiwan’s Industrial Technology Research Institute (ITRI) and Metagone Biotech’s glaucoma and macular degeneration drug development, and Ever Supreme Bio Technology’s cell therapy progress.   New Gongwin-KY lung cancer drug cleared for marketing…

LatAm A breakdown of the investments made by the pharmaceutical industry in clinical studies across the Latin American region. According to the US National Library of Medicine’s ClinicalTrials.gov, USD 1.1 billion were invested in 2019 with Mexico, Brazil and Argentina at the head of the LatAm countries where these investments were…

Global After a turbulent five-year tenure, Kare Schultz will be stepping down as the Israeli generics giant ‘s CEO and former Sandoz chief Richard Francis will take over in January. Francis, who brings his vast industry experience at companies like Sandoz and Biogen to the role, will inherit a number of…

LatAm Florencia Davel, head of LatAm operations for Bristol Myers Squibb (BMS) looks back on a successful four years in position, shaping the regional organisation into a true biopharma player in line with a global strategy shift. Davel also casts her eye over the market access scenario in LatAm, why BMS…

Greece Faye Kosmopolou of Greek generic industry association PEF discusses Greece’s potential as a pharma manufacturing hub for Southeast Europe post-COVID, the challenges of overcoming low generic penetration rates in the domestic market, and why she is optimistic for the future of Greek pharma moving forward.   Greece is the only…

LatAm As selected by the Generics & Biosimilars Initiative (GABI), these are the top ten pharma companies ranked by turnover in Argentina, Brazil, Chile, Colombia, and Mexico for 2021. As the chart shows, the Argentinian and Brazilian Top Tens are dominated by domestic companies, while multinationals hold sway in Colombia and…

Egypt As Egypt moves towards universal healthcare coverage for its 100 million-plus population, the country has become the fastest growing pharma market in the Middle East and Africa region with a value of USD 6.3 billion. Here are some of the key trends to watch in Egypt as identified by local…

Americas The Head of Viatris Latin America, Patrick Doyle, spoke to PharmaBoardroom about setting up the two-year old company’s Latam affiliate during the pandemic, the decision to focus on specific therapeutic areas—cardiovascular disease, central nervous system (CNS) disorders, and pain—in LatAm and Viatris’ aim to partner with local stakeholders and go…

Egypt PhRMA’s Middle East & Africa (MEA) group appoints a ‘champion’ for each of its markets to bring the priorities of that country to the agenda of the MEA executive committee. Egypt’s champion is Amgen and – as the company’s MEA lead Mohammed Nasser describes – there is much to be…